Clinical characteristics of the thyroid follicular carcinoma
Main Article Content
Keywords
Carcinoma, papillary, follicular, Thyroid neoplasms
Abstract
Background: the prevalence of thyroid follicular carcinoma (TFC) is 39 % in patients with an undetermined histological diagnosis. The aim was to know the prevalence of TFC in a hospital with high population concentration.
Methods: surgical reports with a final diagnosis of TFC were reviewed. The size of the tumor, age, gender, pre and post-surgical diagnosis and comorbidities were retrieved.
Results: a total of 35 reports with a diagnosis of TFC were found, 30 (85 %) were females with a mean age 44 ± 16.9 years. The mean age was 57 ± 6.6 in males. The diagnoses before surgery were follicular carcinoma 14 (40 %), thyroid cancer 6 (17.1 %), thyroid adenoma 4 (11.4 %), goiter 3 (8.5 %), thyroid nodule 3 (8.5 %), one papillary carcinoma (2.8 %), one thyroid neoplasm (2.8 %), one poorly differentiated adenocarcinoma (2.8 %), one well differentiated follicular adenocarcinoma (2.8 %), and one medullary thyroid cancer (2.8 %). The comorbidities found were Hashimoto disease 2 (5.6 %) and papillary contralateral carcinoma 2 patients (5.6 %).
Conclusions: follicular carcinomas of the thyroid of our population differ in clinical presentation compared with previous reports.
References
Mackenzie EJ, Mortimer RH. Thyroid nodules and thyroid cancer. Med J Aust. 2004;180(5):242-7.
Hagedus L. The thyroid nodule. N Engl J Med 2004;351(17):1764-71.
Castro M, Hossein G. Continuing controversies in the management of thyroid nodules. Ann Intern Med. 2005;142(11):926-31.
Sherman SI. Thyroid carcinoma. Lancet. 2003;361 (9356):501-11.
Grebe SK, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am. 1995;24(4):761-801.
Collini P, Sampietro G, Rosai J, Pilotti S. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch 2003;442(1):71-6.
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al., editores. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004. Disponible en Surveillance Epidemiology and End Results. [Sitio web]. http://seer.cancer.gov/csr/1975_2001/
Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid. 2001;11(7):
637-45.
Mazzaferri EL. Thyroid carcinoma: papillary and follicular. En: Mazzaferri EL, Samaan N, editores. Endocrine tumors. Cambridge, MA: Blackwell Scientific; 1993. p. 278-333.
Medema RH, Bos JL. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog. 1993;4(6):615-61.
García-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21(17):3226-35.
Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120(1):71-7.
Pettersson B, Adami HO, Wilander E, Coleman MP. Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type. Int J Cancer. 1991;48(1):28-33.
Singer PA. Thyroid nodules: malignant or benign? Hosp Pract. 1998;33(1):143-4,147-8,153-6.
Tamez-Pérez HE, Gutiérrez-Hermosillo H, Forsbach-Sánchez G, et al. Citología por aspiración con aguja fina de tiroides “no diagnóstica”: resultados del tratamiento quirúrgico. Rev Invest Clin. 2007;59(3):180-3.
Harach HR, Escalante DA, Onativia A, Lederer-Outes J, Saravia-Day E, Williams ED. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinol. 1985;108(1):55-60.
Ronckers C, Ron E. Thyroid cancer. En: Freedman LS, Edwards BK, Ries LAG, Young JL, editores. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. Bethesda, MD: National Cancer Institute. NIH Pub. No. 06-5873. [Internet]. p. 121-30. [Consultado el 3 de septiembre de 2008]. Disponible en http://seer.cancer.gov/publications/mecc/mecc_monograph.pdf